Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Sarcoma, Ewing 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 127Carboplatin 125Pemetrexed 105Cisplatin 79Paclitaxel 58osimertinib 55Nivolumab 52Docetaxel 52durvalumab 48Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 35Radiosurgery 29atezolizumab 27Cetuximab 26130-nm albumin-bound paclitaxel 26Radiotherapy 22Ipilimumab 21Drug Therapy 21cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Biopsy 12lazertinib 11Radiation 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × romiplostim × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡